Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Times Guadeloupe.
Press releases published on July 18, 2025
SAPU Bioscience 重點報導經同業-評審的出版刊物，指出 TGFB2 與年輕胰臟癌患者的存活期息息相關
GlobeNewswire
·
July 18, 2025
數據支持進一步評估試驗性的反義寡核苷酸 OT-101 (trabedersen) 作為胰臟導管腺癌中 TGFB2- 標靶治療方案的效果。 聖地亞哥，加州, July 19, 2025 (GLOBE NEWSWIRE) -- GMP Biotechnology Limited (GMP Bio) 的全資附屬公司 Sapu Biosciences, LLC (Sapu)，與開發針對癌症及罕見疾病的 RNA -標靶和小-分子療法的臨床-階段生物製藥公司 Oncotelic Therapeutics, Inc. ( …
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
·
July 18, 2025
SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL …
US Wearable Technology market to grow at a CAGR of 15.4%: Wissen Research
GlobeNewswire
·
July 18, 2025
Sheridan, July 18, 2025 (GLOBE NEWSWIRE) -- According to the latest global wearable market report published by Wissen Research, the US wearable technology market was valued at USD 24 billion in 2024 and is expected to grow at a CAGR of 15.4% during the …
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
July 18, 2025
NOVATO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of …
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
GlobeNewswire
·
July 18, 2025
NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseases, …
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
July 18, 2025
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of July 17, 2025, the Compensation Committee of the …
Human Appeal USA Mobilizes Relief and Volunteer Event for Texas Flood Victims
GlobeNewswire
·
July 18, 2025
DALLAS, July 18, 2025 (GLOBE NEWSWIRE) -- In the wake of devastating floods across Texas, including persistent overflow from the Guadalupe River, Dallas-based nonprofit Human Appeal USA is taking action to support affected families with both on-the-ground …
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
GlobeNewswire
·
July 18, 2025
Company announcement – No. 17 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, July 18, 2025 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the …
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GlobeNewswire
·
July 18, 2025
STAMFORD, Conn., July 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck, announced today that the European Commission (EC) granted conditional marketing authorization for EZMEKLY® (mirdametinib) for the treatment of …
Muscle Gain & Strength Supplements: How CrazyBulk Muscle Building Supplements Boost Strength and Maximize Muscle Performance Fast
GlobeNewswire
·
July 18, 2025
New York City, NY, July 18, 2025 (GLOBE NEWSWIRE) -- In the ever-evolving world of muscle building, performance, and strength enhancement, CrazyBulk has emerged as the name reshaping the conversation around legal supplements. As fitness communities move …
EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
GlobeNewswire
·
July 18, 2025
EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to market EURneffy in the U.K., expects availability in late …
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
GlobeNewswire
·
July 18, 2025
SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory …
Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors
GlobeNewswire
·
July 18, 2025
SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene …
Generation Bio Announces 1-for-10 Reverse Stock Split
GlobeNewswire
·
July 18, 2025
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced that it will implement a 1-for-10 …
Inspira Regains Compliance with Nasdaq Minimum Bid Price Requirement
GlobeNewswire
·
July 18, 2025
RA'ANANA, Israel, July 18, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it has …
Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
GlobeNewswire
·
July 18, 2025
SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today announced …
Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)
GlobeNewswire
·
July 18, 2025
CELEBRATION, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, announced that three posters on MIPLYFFA® …
Kraig Biocraft Laboratories Nears Strategic Three-Year Government Collaboration to Expand Recombinant Spider Silk Production
GlobeNewswire
·
July 18, 2025
ANN ARBOR, Mich., July 18, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it is finalizing a significant three-year collaborative agreement …
FOXO TECHNOLOGIES INC. ANNOUNCES INTENTION TO SPIN OFF EPIGENETICS SUBSIDIARY
GlobeNewswire
·
July 18, 2025
WEST PALM BEACH, FLORIDA, July 18, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”), today announced that its Board of Directors has approved pursuing the spin-off of its FOXO Labs, Inc. subsidiary that is …
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada
GlobeNewswire
·
July 18, 2025
MONTREAL, July 18, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that Knight's New Drug Submission (NDS) for CREXONT® has been accepted for review by …